We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Horizon Strengthens Board with Appointment of Dr. Ian Gilham
News

Horizon Strengthens Board with Appointment of Dr. Ian Gilham

Horizon Strengthens Board with Appointment of Dr. Ian Gilham
News

Horizon Strengthens Board with Appointment of Dr. Ian Gilham

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Horizon Strengthens Board with Appointment of Dr. Ian Gilham"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Horizon Discovery (Horizon) has announced the appointment of Dr. Ian Gilham as a non-executive director.

Ian is currently non-executive chairman of Multiplicom NV, focused on the development and commercialization of DNA sequencing products; and Biosurfit SA, focused on development and commercialization of point-of-care diagnostic products.

He is also Director of Stowheath Ltd., which offers advisory services to private equity companies and corporate finance organizations investing in clinical diagnostics and medical device companies.

Ian has previously been CEO of Axis-Shield plc and Vice President, Pharmacogenetics and Diagnostics at GSK, as well as holding various positions within Abbott Laboratories.

Commenting on the announcement, Dr. Darrin M Disley, CEO of Horizon said: “I would like to welcome Ian to Horizon’s board of directors. His commercial and investor relations experience will be highly valuable to the company as we continue to develop as a world-leading translational genomics organization.”

Dr. Gilham noted: “Horizon is one of the UK’s most promising life science companies. I’m delighted to join the board at this stage of the organization’s development.”

Horizon’s mission is to provide its customers with cutting-edge biological tools and services that will accelerate the pace of development of ‘personalized’ medicines.

Advertisement